Jazz to Withdraw Zepzelca Second-Line SCLC Approval After Second Confirmatory Trial Failure

Jazz Pharmaceuticals (JAZZ) will voluntarily withdraw Zepzelca’s (lurbinectedin) accelerated approval in second-line small cell lung cancer after the Phase 3 LAGOON trial failed to meet its overall survival primary endpoint. The withdrawal, which Jazz plans to submit in Q3 2026, does not affect the drug’s separate first-line maintenance approval with Roche’s Tecentriq. JAZZ shares closed at $256.56 on August 7.

Zepzelca received accelerated approval in June 2020 based on a 35% overall response rate in a 105-patient single-arm trial. The FDA required confirmatory trials as a condition of staying on the market. The first confirmatory attempt, the Phase 3 Atlantis trial testing lurbinectedin plus doxorubicin, failed in 2021. The FDA allowed the drug to remain available, citing use of a lower dose in Atlantis and unmet need in the second-line setting.

The LAGOON trial (N=724) was the second attempt, testing standard-dose Zepzelca monotherapy and Zepzelca plus irinotecan against the investigator’s choice of topotecan or irinotecan. The monotherapy arm performed worse than the control arm. The combination arm showed a numerical advantage that did not reach statistical significance. With two confirmatory failures and Amgen’s Imdelltra now approved as standard therapy in previously treated SCLC, the FDA’s case for allowing a third chance evaporated.

Zepzelca still generated $106 million in Q2 2026 revenue, up 42% year over year. But 60% to 70% of that came from second-line use, according to Jazz’s chief commercial officer on the Q2 earnings call. The withdrawal opens a revenue gap the first-line maintenance indication must fill. Second-line prescribing had already been declining due to competition and Jazz expects it to “accelerate” now.

The first-line maintenance indication, approved in 2025 based on the IMforte trial, is now Zepzelca’s sole growth driver. That trial showed a statistically significant overall survival benefit for lurbinectedin plus Tecentriq versus Tecentriq alone in extensive-stage SCLC. But the commercial ramp of the maintenance regimen has been slower than the second-line business it must replace, and Jazz faces the task of convincing oncologists to adopt the combination in a setting where Tecentriq alone isn’t standard of care.

The story is part of a broader FDA push to enforce confirmatory trial requirements for accelerated approvals. GSK withdrew Blenrep in 2022 after its confirmatory trial failed; Gilead pulled Trodelvy’s bladder cancer indication on similar grounds. Zepzelca’s saga is notable for lasting six years and surviving one failed confirmatory trial before the FDA drew the line at a second miss.

Jazz’s other major catalyst — the FDA decision on zanidatamab (Ziihera) for first-line gastroesophageal adenocarcinoma — resolved on August 25 with approval. Read our Ziihera approval coverage and the pre-decision analysis.

Source: Jazz Pharmaceuticals Q2 2026 earnings / FiercePharma